ArticleJMIR human factors2025
TeleAllergy: Potential of Telemedicine in Management of Patients With Allergies.
Article in JMIR human factors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing prevalence of allergic diseases alongside a shortage of trained allergists creates significant challenges in delivering timely care, especially for underserved populations. Telemedicine presents a promising solution, offering remote care through digital tools. While telemedicine has been widely adopted in other fields, its use in allergy care remains underexplored. Objective: This study aimed to assess the potential of telemedicine in managing allergic diseases by examining patient preferences and experiences. Methods: A survey of 27 questions was distributed to adult patients (>18 y) with allergic diseases attending the outpatient allergy clinic at the Division of Allergy, University Hospital Basel, Basel, Switzerland, between May and August 2024. The survey covered demographic information, prior use of telemedicine, and preferences for teleconsultation modalities. It also assessed patients' willingness to share various types of clinical data, including images and written reports, and explored which allergic diseases were considered appropriate for telemedicine. Results: A total of 102 patients participated in the survey, with a mean age of 44.4 years (SD 16.7 y). For further analysis, the patients were stratified into four age groups: 18-34 years (36/102), 35-49 years (26/102), 50-64 years (31/102), and ≥65 years (9/102). Among them, 44% (41/94; P=.22) had previously used telemedicine services, with 34% (32/94; P=.04) specifically using it for allergic diseases. When asked about consultation formats, 49% (49/100) of patients preferred in-person visits, while 41% (41/100) favored a hybrid model combining telemedicine and in-person care. Regarding telemedicine tools, 57% (51/89) preferred telephone consultations with a doctor. Patients would use telemedicine preferentially for mild compared to severe allergic diseases as well as for chronic compared to acute conditions. The spectrum of diseases for which patients would use telemedicine comprised a wide range of allergic conditions, with allergic rhinoconjunctivitis (16%; 14/85), Hymenoptera venom allergy (13%; 11/85), and food allergy/intolerance (13%; 11/85) cited most frequently. Only 7% (6/85) of patients indicated they would not use telemedicine for any allergic disease. Conclusions: This study emphasizes the growing adoption and importance of telemedicine in allergy care, with a significant proportion of patients already having experience using it for managing allergic diseases. Patients' inclination toward multiple communication formats underscores the growing need for individualized management of allergic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.